Lugano, Switzerland, 24 February 2025 – The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours.
Programme picks
- New insights on combination strategies with antibody-drug conjugates (ADCs) for treating HER2+ metastatic breast cancer and advanced or metastatic non-small cell lung cancer, along with discussions on emerging combination drugs in molecular oncology.
- Early findings on the anticancer activity of a therapy combining PARP and VEGFR inhibitors in heavily pretreated patients with ovarian and prostate cancers.
- Related content: Abstract 28O
- The role of artificial intelligence in drug development and in predicting survival outcomes in metastatic renal cell carcinoma and treatment side-effects in melanoma.
- Results on the effectiveness of a new type of ‘off-the-shelf’ CAR-T cell for myeloma.
- Related content: Abstract 22O
- Insights on the opportunities and challenges of radiotheranostics in cancer treatment: from molecular imaging for patient selection to novel targets and logistical challenges for radiopharmaceutical supply.
- Related content: Session on 5 March, 8:45 – 10:15 CET
Award keynote lecture
- “Bridging cancer genomics and drug development: An academic perspective” by Philippe L. Bedard, recipient of the 2025 TAT Honorary Award, 3 March 2025, 13:05 – 13:40 CET
Keynote lecture
- “Revolutionising cancer treatment: The transformative odyssey of tumor-agnostic drug development in precision medicine” by Vivek Subbiah, 4 March 2025, 14:25 – 14:55 CET
The results of studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO TAT 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO TAT 2025 and the official congress hashtag #ESMOTAT25. Follow it to stay up to date and use it to take part in the conversation on X(Twitter), LinkedIn, Facebook, Instagram, YouTube.